Suggested remit: To appraise the clinical and cost effectiveness of nivolumab with chemotherapy within its marketing authorisation for treatment of early non-small cell lung cancer.
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
| Process |
STA
|
| ID number |
3757
|
Project Team
| Project lead |
Emily Richards |
Email enquiries
|
Date
|
Update
|
|
13 April 2022 - 13 May 2022
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
|
23 February 2022
|
As you will be aware, The Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab with chemotherapy for neoadjuvant treatment of early non-small-cell lung cancer.
Following information received from the company this appraisal has been scheduled into the work programme. The appraisal is anticipated to begin in mid-July 2022.
|
|
25 March 2021
|
The National Institute for Health and Care Excellence (NICE) has been asked to consider an appraisal of nivolumab with chemotherapy for neoadjuvant treatment of early non-small-cell lung cancer. We have recently invited stakeholders to respond to a written consultation on the draft scope for this appraisal.
Following the receipt of an update from the company that market nivolumab, NICE has agreed that continuing the scoping exercise at this time would not be appropriate. As a consequence of this, the scoping exercise has been cancelled and will be rearranged at a later date. Please accept our apologies for any inconvenience.
If you have any comments or concerns, please contact the project manager for this proposed appraisal Emily Richards on (44 (0)161 413 4070 or via email on emily.richards@nice.org.uk).
|
|
04 September 2020
|
The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of nivolumab with chemotherapy for neoadjuvant treatment of early non-small-cell lung cancer ID3757. We have recently invited stakeholders to respond to a written consultation on the draft scope for this appraisal.
On receiving updated regulatory timing information from the company that market nivolumab, NICE has agreed that continuing the scoping exercise at this time would not be appropriate. As a consequence of this we have stopped the scoping exercise for this topic. We apologise for any inconvenience this may cause. Scoping will be rearranged for later date in line with anticipated regulatory approval timings.
If you have any comments or concerns please contact the project manager for this proposed appraisal Emily Richards on (44 (0)161 413 4070 or via email on emily.richards@nice.org.uk)
|
|
03 March 2020
|
In progress. DHSC referral received |
|
25 February 0221 - 25 March 0221
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual